On the public citation graph

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

https://doi.org/10.1056/nejmc2112186
0 signed · 194 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1056/nejmoa1913556openalex-snapshot
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
inferredcites →https://doi.org/10.1056/nejmoa2110275openalex-snapshot
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
inferredcites →https://doi.org/10.1097/inf.0000000000001916openalex-snapshot
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4749763openalex-extracted
inferred← citeshttps://doi.org/10.1001/jama.2025.24082openalex-snapshot
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
inferred← citeshttps://doi.org/10.1002/14651858.cd009417.pub3openalex-snapshot
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
inferred← citeshttps://doi.org/10.1002/jcph.2401openalex-snapshot
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants
inferred← citeshttps://doi.org/10.1002/mco2.70403openalex-snapshot
Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals
inferred← citeshttps://doi.org/10.1002/ped4.12377openalex-snapshot
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
inferred← citeshttps://doi.org/10.1002/ppul.71215openalex-snapshot
Viral Bronchiolitis in Infants in the Era of Targeted Therapies: What Now and What's Next?
inferred← citeshttps://doi.org/10.1002/rmv.2576openalex-snapshot
Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development
inferred← citeshttps://doi.org/10.1007/978-3-031-84089-0_11openalex-snapshot
Community-Acquired Pneumonia
inferred← citeshttps://doi.org/10.1007/s00112-024-01952-6openalex-snapshot
Prävention von Infektionen mit dem respiratorischen Synzytialvirus im Kindesalter
inferred← citeshttps://doi.org/10.1007/s00246-023-03388-3openalex-snapshot
Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
inferred← citeshttps://doi.org/10.1007/s00431-022-04797-xopenalex-snapshot
Prematurity and BPD: what general pediatricians should know
inferred← citeshttps://doi.org/10.1007/s00431-025-06440-xopenalex-snapshot
Impact of nirsevimab immunoprophylaxis on respiratory syncytial virus-related outcomes in hospital and primary care after two consecutive seasons: a population-based retrospective cohort study in infants in their second year of life in Catalonia, Spain
inferred← citeshttps://doi.org/10.1007/s00431-025-06581-zopenalex-snapshot
Adherence to the nirsevimab immunization campaign: analysis of sociodemographic and medico-economic influences—single-centre prospective cohort study in France
inferred← citeshttps://doi.org/10.1007/s00608-024-01224-2openalex-snapshot
Empfehlungen der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde zur Prophylaxe einer RSV-Infektion mit Nirsevimab
inferred← citeshttps://doi.org/10.1007/s12325-024-02798-wopenalex-snapshot
Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study
inferred← citeshttps://doi.org/10.1007/s12519-025-00926-2openalex-snapshot
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants
inferred← citeshttps://doi.org/10.1007/s12519-025-00997-1openalex-snapshot
Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy
inferred← citeshttps://doi.org/10.1007/s40121-022-00737-2openalex-snapshot
Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities
inferred← citeshttps://doi.org/10.1007/s40121-025-01134-1openalex-snapshot
Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan
inferred← citeshttps://doi.org/10.1007/s40121-025-01194-3openalex-snapshot
Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK
inferred← citeshttps://doi.org/10.1007/s40121-026-01311-wopenalex-snapshot
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study
inferred← citeshttps://doi.org/10.1007/s40261-025-01437-8openalex-snapshot
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants
inferred← citeshttps://doi.org/10.1007/s40265-022-01829-6openalex-snapshot
Nirsevimab: First Approval
inferred← citeshttps://doi.org/10.1007/s40267-023-01039-4openalex-snapshot
Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use
inferred← citeshttps://doi.org/10.1007/s40588-025-00245-0openalex-snapshot
Prophylaxis of RSV Infection in Infants
inferred← citeshttps://doi.org/10.1007/s40588-026-00272-5openalex-snapshot
Prevention of RSV Infection Using Long-acting Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.09.005openalex-snapshot
Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2023–2024 season
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.09.006openalex-snapshot
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.10.011openalex-snapshot
Recommendations of the Spanish Society of Pediatric Cardiology and Congenital Heart Diseases for the prevention of respiratory syncytial virus infections with nirsevimab in pediatric cardiology
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.09.001openalex-snapshot
Recomendaciones de la Sociedad Española de Neonatología para la profilaxis frente a las infecciones graves por virus respiratorio sincitial con nirsevimab, para la estación 2023-2024
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.09.006openalex-snapshot
Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología Pediátrica
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.10.006openalex-snapshot
Recomendaciones de la Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas sobre la profilaxis de la infección por virus respiratorio sincitial con nirsevimab en cardiología pediátrica
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105791openalex-snapshot
Current state and challenges in respiratory syncytial virus drug discovery and development
inferred← citeshttps://doi.org/10.1016/j.arcmed.2025.103183openalex-snapshot
Mexican Interdisciplinary Consensus on the Diagnosis and Preventive Measures for Respiratory Syncytial Virus Infections
inferred← citeshttps://doi.org/10.1016/j.cmi.2023.08.028openalex-snapshot
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102986openalex-snapshot
Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France
inferred← citeshttps://doi.org/10.1016/j.ijid.2024.107118openalex-snapshot
Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ijregi.2024.100357openalex-snapshot
Impact of pneumococcal conjugate vaccine 13 introduction on severe lower respiratory tract infections associated with respiratory syncytial virus or influenza virus in hospitalized children in Ulaanbaatar, Mongolia
inferred← citeshttps://doi.org/10.1016/j.jbc.2023.105270openalex-snapshot
Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors
inferred← citeshttps://doi.org/10.1016/j.jbc.2025.108205openalex-snapshot
An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling
inferred← citeshttps://doi.org/10.1016/j.jiac.2024.05.008openalex-snapshot
Review of the past and present status of respiratory syncytial virus and rotavirus infections that commonly affect children
inferred← citeshttps://doi.org/10.1016/j.jinf.2024.106180openalex-snapshot
Clinical characteristics and outcomes of respiratory syncytial virus-associated ARF in immunocompetent patients: A seven-year experience at a tertiary hospital in France
inferred← citeshttps://doi.org/10.1016/j.jvacx.2025.100731openalex-snapshot
Real-world data and clinical management experience in passive immunization for respiratory syncytial virus prevention in children
inferred← citeshttps://doi.org/10.1016/j.lanepe.2024.101007openalex-snapshot
Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study
inferred← citeshttps://doi.org/10.1016/j.pedhc.2024.11.005openalex-snapshot
Practical Application of Nirsevimab Recommendations for Infants and Toddlers
inferred← citeshttps://doi.org/10.1016/j.pedneo.2025.10.004openalex-snapshot
Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs
inferred← citeshttps://doi.org/10.1016/j.perped.2023.07.005openalex-snapshot
Prévention des infections à VRS chez l’enfant : quoi de neuf ?
inferred← citeshttps://doi.org/10.1016/j.semperi.2023.151820openalex-snapshot
Outpatient management of established bronchopulmonary dysplasia: An update
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.09.003openalex-snapshot
Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.09.040openalex-snapshot
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.126276openalex-snapshot
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127591openalex-snapshot
Safety of timely immunization with nirsevimab in hospitalized preterm infants
inferred← citeshttps://doi.org/10.1016/j.vaccine.2026.128468openalex-snapshot
Post-licensure safety monitoring of nirsevimab in Western Australia 2024
inferred← citeshttps://doi.org/10.1016/s1473-3099(26)00253-7openalex-snapshot
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
inferred← citeshttps://doi.org/10.1016/s2352-4642(22)00321-2openalex-snapshot
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c00692openalex-snapshot
Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile
inferred← citeshttps://doi.org/10.1021/mc-2023-vol58.ch25openalex-snapshot
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
inferred← citeshttps://doi.org/10.1038/s41467-024-53082-yopenalex-snapshot
How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody
inferred← citeshttps://doi.org/10.1038/s41541-023-00734-7openalex-snapshot
The road to approved vaccines for respiratory syncytial virus
inferred← citeshttps://doi.org/10.1038/s41564-024-01722-wopenalex-snapshot
Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies
inferred← citeshttps://doi.org/10.1055/a-1869-8593openalex-snapshot
RSV-Prophylaxe mit Nirsevimab bei späten Frühund reifen Neugeborenen
inferred← citeshttps://doi.org/10.1055/a-2254-5730openalex-snapshot
Impfung gegen RSV-Infektionen – Update und Ausblick
inferred← citeshttps://doi.org/10.1055/a-2276-5929openalex-snapshot
Impfungen gegen das Respiratorische Synzytial-Virus
inferred← citeshttps://doi.org/10.1055/a-2531-0968openalex-snapshot
Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations
inferred← citeshttps://doi.org/10.1055/s-0042-1757279openalex-snapshot
Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab
inferred← citeshttps://doi.org/10.1056/evide2400440openalex-snapshot
Nirsevimab for Respiratory Syncytial Virus Prophylaxis in Newborns and Infants
inferred← citeshttps://doi.org/10.1056/evidoa2400275openalex-snapshot
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants
inferred← citeshttps://doi.org/10.1056/nejmc2400983openalex-snapshot
Nirsevimab for Prevention of RSV Hospitalizations in Infants
inferred← citeshttps://doi.org/10.1056/nejmoa2309189openalex-snapshot
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
inferred← citeshttps://doi.org/10.1056/nejmoa2314885openalex-snapshot
Nirsevimab and Hospitalization for RSV Bronchiolitis
inferred← citeshttps://doi.org/10.1080/13696998.2023.2242169openalex-snapshot
Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program
inferred← citeshttps://doi.org/10.1080/14760584.2026.2694387openalex-snapshot
Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF
inferred← citeshttps://doi.org/10.1080/14787210.2026.2694632openalex-snapshot
Palivizumab for respiratory syncytial virus immunoprophylaxis in high-risk populations in Qatar: a call for action
inferred← citeshttps://doi.org/10.1080/17476348.2026.2699460openalex-snapshot
Improving the follow-up of children and adults with prematurity-associated lung disease
inferred← citeshttps://doi.org/10.1080/19420862.2022.2153410openalex-snapshot
Antibodies to watch in 2023
inferred← citeshttps://doi.org/10.1080/21645515.2022.2079322openalex-snapshot
RSV disease in infants and young children: Can we see a brighter future?
inferred← citeshttps://doi.org/10.1080/21645515.2023.2209000openalex-snapshot
Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections
inferred← citeshttps://doi.org/10.1080/21645515.2023.2252289openalex-snapshot
Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
inferred← citeshttps://doi.org/10.1080/21645515.2024.2341505openalex-snapshot
Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody
inferred← citeshttps://doi.org/10.1080/21645515.2024.2348135openalex-snapshot
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
inferred← citeshttps://doi.org/10.1080/21645515.2025.2521920openalex-snapshot
Respiratory syncytial virus immunization in children: The old, the new and what’s just around the corner
inferred← citeshttps://doi.org/10.1080/21645515.2025.2545637openalex-snapshot
Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea
inferred← citeshttps://doi.org/10.1080/21645515.2025.2569734openalex-snapshot
Social media insights on the introduction of RSV immunoprophylaxis in Italy
inferred← citeshttps://doi.org/10.1080/21645515.2026.2726689openalex-snapshot
Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review
inferred← citeshttps://doi.org/10.1080/22221751.2023.2231573openalex-snapshot
Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
inferred← citeshttps://doi.org/10.1080/23744235.2025.2580945openalex-snapshot
Updated Swedish guidelines for the management and treatment of RSV infection
inferred← citeshttps://doi.org/10.1089/ped.2024.0025openalex-snapshot
Nirsevimab: A Review
inferred← citeshttps://doi.org/10.1093/ajhp/zxag019openalex-snapshot
Recent developments in pediatric respiratory syncytial virus prevention: The expanding role of monoclonal antibodies
inferred← citeshttps://doi.org/10.1093/femsml/uqaf003openalex-snapshot
Respiratory syncytial virus: health burden, disease prevention, and treatment—recent progress and lessons learned
inferred← citeshttps://doi.org/10.1093/infdis/jiac120openalex-snapshot
Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample
inferred← citeshttps://doi.org/10.1093/infdis/jiac127openalex-snapshot
Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018
inferred← citeshttps://doi.org/10.1093/infdis/jiac155openalex-snapshot
Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011–2019
inferred← citeshttps://doi.org/10.1093/infdis/jiac211openalex-snapshot
The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis
inferred← citeshttps://doi.org/10.1093/infdis/jiac216openalex-snapshot
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
inferred← citeshttps://doi.org/10.1093/infdis/jiac252openalex-snapshot
Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective
inferred← citeshttps://doi.org/10.1093/infdis/jiad367openalex-snapshot
Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011–2017
inferred← citeshttps://doi.org/10.1093/jac/dkad076openalex-snapshot
Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants
inferred← citeshttps://doi.org/10.1093/jpids/piad052openalex-snapshot
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
inferred← citeshttps://doi.org/10.1093/jpids/piae030openalex-snapshot
New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy
inferred← citeshttps://doi.org/10.1093/jpids/piag008openalex-snapshot
Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003354openalex-snapshot
Landscape of respiratory syncytial virus
inferred← citeshttps://doi.org/10.1097/inf.0000000000004715openalex-snapshot
Active Post-marketing Safety Surveillance of Nirsevimab Administered to Children in Western Australia, April–July 2024
inferred← citeshttps://doi.org/10.1097/mot.0000000000001106openalex-snapshot
Respiratory viral infections including COVID-19 in solid organ transplantation
inferred← citeshttps://doi.org/10.1099/jgv.0.002095openalex-snapshot
Recent advances in the prevention and treatment of respiratory syncytial virus disease
inferred← citeshttps://doi.org/10.1111/apa.70725openalex-snapshot
The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis
inferred← citeshttps://doi.org/10.1111/cts.70095openalex-snapshot
A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
inferred← citeshttps://doi.org/10.1111/cts.70231openalex-snapshot
EDP ‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV : Results From a Phase 1 Study in Healthy Adults
inferred← citeshttps://doi.org/10.1111/jpc.16643openalex-snapshot
Nirsevimab: Alleviating the burden of RSV morbidity in young children
inferred← citeshttps://doi.org/10.1126/sciimmunol.adz4626openalex-snapshot
Maternal allergy and neonatal RSV infection synergize via FcR-mediated allergen uptake to promote the development of asthma in early life
inferred← citeshttps://doi.org/10.1136/archdischild-2024-326964openalex-snapshot
Prevention of respiratory syncytial virus disease by immunisation
inferred← citeshttps://doi.org/10.1136/archdischild-2024-327153openalex-snapshot
Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
inferred← citeshttps://doi.org/10.1136/bmj.o590openalex-snapshot
Sixty seconds on . . . RSV
inferred← citeshttps://doi.org/10.1136/bmjph-2024-002441openalex-snapshot
Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost–utility modelling study
inferred← citeshttps://doi.org/10.1136/bmjresp-2022-001457openalex-snapshot
Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK
inferred← citeshttps://doi.org/10.1146/annurev-med-061323-073934openalex-snapshot
New Approaches to Respiratory Syncytial Virus Prevention and Treatment
inferred← citeshttps://doi.org/10.1152/physiolgenomics.00045.2024openalex-snapshot
Association of SNP-SNP interactions of surfactant protein genes with severity of respiratory syncytial virus infection in children
inferred← citeshttps://doi.org/10.1177/00185787231212620openalex-snapshot
Formulary Drug Reviews: Nirsevimab
inferred← citeshttps://doi.org/10.1177/10600280241243357openalex-snapshot
Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children
inferred← citeshttps://doi.org/10.1186/s12879-023-08024-2openalex-snapshot
Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study
inferred← citeshttps://doi.org/10.1186/s12879-024-09642-0openalex-snapshot
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain
inferred← citeshttps://doi.org/10.1186/s12879-024-10120-wopenalex-snapshot
RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial
inferred← citeshttps://doi.org/10.1186/s12879-025-12243-0openalex-snapshot
Standardized vaccination practices for preterm infants: Egyptian experts’ consensus
inferred← citeshttps://doi.org/10.1186/s13052-024-01593-1openalex-snapshot
Knowledge, attitudes and behaviours of a sample of Italian paediatricians towards RSV and its preventive strategies: a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s13052-025-01844-9openalex-snapshot
Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection
inferred← citeshttps://doi.org/10.1186/s41479-025-00160-4openalex-snapshot
Prevention of respiratory syncytial virus disease across the lifespan in Italy
inferred← citeshttps://doi.org/10.12677/acm.2025.1551343openalex-snapshot
Advances in the Research on Risk Factors for Severe Infections Caused by Respiratory Syncytial Virus in Infants and Young Children
inferred← citeshttps://doi.org/10.12775/jehs.2024.76.56570openalex-snapshot
Prevention of Lower Respiratory Tract Diseases caused by RSV in Infants in Poland: A Review of Current Recommendations
inferred← citeshttps://doi.org/10.12968/hmed.2024.0141openalex-snapshot
The respiratory consequences of preterm birth: from infancy to adulthood
inferred← citeshttps://doi.org/10.14776/piv.2023.30.e2openalex-snapshot
Recent Advances in the Prevention of RSV in Neonates and Young Infants
inferred← citeshttps://doi.org/10.15167/2421-4248/jpmh2024.65.2.3329openalex-snapshot
First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants
inferred← citeshttps://doi.org/10.1542/hpeds.2024-007739openalex-snapshot
Nirsevimab: The Hidden Costs
inferred← citeshttps://doi.org/10.1542/peds.2024-066461openalex-snapshot
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
inferred← citeshttps://doi.org/10.1542/peds.2024-066508openalex-snapshot
Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children
inferred← citeshttps://doi.org/10.1542/peds.2024-067174openalex-snapshot
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
inferred← citeshttps://doi.org/10.1542/peds.2025-072578openalex-snapshot
Hospitalization Outcomes of Full-Term and Premature Children Aged Less Than 2 Years Hospitalized With RSV
inferred← citeshttps://doi.org/10.15585/mmwr.mm7234a4openalex-snapshot
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
inferred← citeshttps://doi.org/10.1891/nn-2023-0056openalex-snapshot
Balanced on the Biggest Wave: Nirsevimab for Newborns
inferred← citeshttps://doi.org/10.21037/tp-23-534openalex-snapshot
Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
inferred← citeshttps://doi.org/10.2478/abm-2025-0015openalex-snapshot
Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis
inferred← citeshttps://doi.org/10.25259/jvi_2_2026openalex-snapshot
Nirsevimab for RSV Prevention in India: Economic Viability and Implementation Pathways for National Introduction: A Review
inferred← citeshttps://doi.org/10.3238/arztebl.m2024.0060openalex-snapshot
Respiratory syncytial virus-associated respiratory diseases in children and adults
inferred← citeshttps://doi.org/10.32388/pqwebfopenalex-snapshot
Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement)
inferred← citeshttps://doi.org/10.33393/grhta.2025.3182openalex-snapshot
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
inferred← citeshttps://doi.org/10.3346/jkms.2026.41.e317openalex-snapshot
Effectiveness of Nirsevimab in High-Risk Children Under 24 Months for Prevention of Respiratory Syncytial Virus Infection: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1283120openalex-snapshot
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1329426openalex-snapshot
Clinical research on RSV prevention in children and pregnant women: progress and perspectives
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1581970openalex-snapshot
Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3389/fmicb.2023.1327239openalex-snapshot
Epidemiology and molecular analyses of respiratory syncytial virus in the 2021–2022 season in northern Italy
inferred← citeshttps://doi.org/10.3389/fped.2026.1841732openalex-snapshot
A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants
inferred← citeshttps://doi.org/10.3389/fped.2026.1864969openalex-snapshot
Insights Into monoclonal antibodies and vaccines targeting respiratory viruses
inferred← citeshttps://doi.org/10.3389/fphar.2024.1381107openalex-snapshot
Epidemiology of respiratory syncytial virus in hospitalized children over a 9-year period and preventive strategy impact
inferred← citeshttps://doi.org/10.3389/fpubh.2025.1604331openalex-snapshot
The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy
inferred← citeshttps://doi.org/10.3389/fpubh.2025.1641085openalex-snapshot
Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3390/children10071169openalex-snapshot
Respiratory Syncytial Virus: A Systematic Review and Meta-Analysis of Tomographic Findings (2000–2022)
inferred← citeshttps://doi.org/10.3390/children13020173openalex-snapshot
Burden of RSV-Associated Inpatient Care and Emergency Service Utilization in Two German Pediatric Centers Across Six Seasons Including the First Nirsevimab Year
inferred← citeshttps://doi.org/10.3390/children13030331openalex-snapshot
Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months
inferred← citeshttps://doi.org/10.3390/children13091189openalex-snapshot
Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study
inferred← citeshttps://doi.org/10.3390/cimb46090617openalex-snapshot
Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention
inferred← citeshttps://doi.org/10.3390/idr16020026openalex-snapshot
Respiratory Syncytial Virus Infections in Recipients of Bone Marrow Transplants: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/medicina62101858openalex-snapshot
Nirsevimab in the New Era of RSV Prevention: Current Evidence, Emerging Challenges, and Future Perspectives
inferred← citeshttps://doi.org/10.3390/pathogens12020154openalex-snapshot
Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
inferred← citeshttps://doi.org/10.3390/pathogens13060503openalex-snapshot
Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials
inferred← citeshttps://doi.org/10.3390/pediatric14040055openalex-snapshot
Respiratory Syncytial Virus: An Uncommon Cause of Febrile Seizures—Results from a Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3390/pediatric15010013openalex-snapshot
Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians
inferred← citeshttps://doi.org/10.3390/v15112276openalex-snapshot
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
inferred← citeshttps://doi.org/10.3390/v17091236openalex-snapshot
Viral Burden of Respiratory Syncytial Virus and Viral Coinfections as Factors Regulating Paediatric Disease Severity
inferred← citeshttps://doi.org/10.3390/v18090982openalex-snapshot
Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024–2025 Italian Universal Immunization Campaign in Newborns
inferred← citeshttps://doi.org/10.3390/vaccines11121797openalex-snapshot
New Insights on Respiratory Syncytial Virus Prevention
inferred← citeshttps://doi.org/10.3390/vaccines12040383openalex-snapshot
Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.3390/vaccines12060640openalex-snapshot
Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)
inferred← citeshttps://doi.org/10.3390/vaccines13050470openalex-snapshot
Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/vaccines13060623openalex-snapshot
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign
inferred← citeshttps://doi.org/10.3390/vaccines13090888openalex-snapshot
A Review of Insights on Vaccination Against Respiratory Viral Infections in Africa: Challenges, Efforts, Impacts, and Opportunities for the Future
inferred← citeshttps://doi.org/10.3390/vaccines14010059openalex-snapshot
Recommendations on Respiratory Syncytial Virus (RSV) Immunization Strategies for Infants and Young Children in Countries with Year-Round RSV Activity
inferred← citeshttps://doi.org/10.3390/women2020016openalex-snapshot
Respiratory Syncytial Virus in Pregnant Women: Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.35366/118344openalex-snapshot
Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP): prevención de la infección por virus sincitial respiratorio en México, 2024
inferred← citeshttps://doi.org/10.3928/19382359-20250307-02openalex-snapshot
Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population
inferred← citeshttps://doi.org/10.4081/jbr.2026.14042openalex-snapshot
The evolving science of Clesrovimab: pharmacological insights and clinical implications
inferred← citeshttps://doi.org/10.53126/meb41632openalex-snapshot
La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab
inferred← citeshttps://doi.org/10.53126/meb42150openalex-snapshot
Lettere
inferred← citeshttps://doi.org/10.57598/r402copenalex-snapshot
Cost-effectiveness of Abrysvo® and Beyfortus® against RSV infections in Belgian infants
inferred← citeshttps://doi.org/10.6084/m9.figshare.22615796openalex-snapshot
Additional file 1 of Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study
inferred← citeshttps://doi.org/10.6084/m9.figshare.26687208openalex-snapshot
Additional file 1 of Knowledge, attitudes and behaviours of a sample of Italian paediatricians towards RSV and its preventive strategies: a cross-sectional study
inferred← citeshttps://doi.org/10.64898/2026.09.07.749649openalex-snapshot
Pan-neutralization of parainfluenza viruses by a hemagglutinin-neuraminidase antibody
inferred← citeshttps://doi.org/10.69854/jcq.2026.0001openalex-snapshot
Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis
inferred← citeshttps://doi.org/10.70675/1806c010z53a0z43b8zbfecz3e5a833ac3b1openalex-snapshot
Etude structurale et fonctionnelle de la nucléocapside du virus respiratoire syncytial
inferred← citeshttps://doi.org/10.70675/ba0b1a9aze15fz4992za762z54de8880efd5openalex-snapshot
Régulation fine de la nucléoprotéine du virus respiratoire syncytial par des modifications post-traductionnelles et des protéines cellulaires
inferred← citeshttps://doi.org/10.7499/j.issn.1008-8830.2405078openalex-snapshot
[Expert recommendations for the prevention of common respiratory viral infections in neonates].
inferred← citeshttps://doi.org/10.7499/j.issn.1008-8830.2409033openalex-snapshot
[Interpretation of "Expert recommendations for the prevention of common respiratory viral infections in neonates": problems faced by respiratory syncytial virus infection in neonates].
inferred← citeshttps://doi.org/10.7759/cureus.97521openalex-snapshot
The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.